To evaluate the effects of these mAbs on the spread of pathological tau in vivo, 5xFAD mice harboring significant brain Aβ plaque burden were unilaterally injected with AD-tau in the hippocampus, to initiate the formation of neuritic plaque (NP) tau pathology, and were treated weekly with intraperitoneal (i.p.)injections of DMR7, SKT82, or IgG isotype control mAbs. This evidence concerns the gene MAPT and Alzheimer disease.